蛋白多肽类药物脂质体中国专利技术研究进展  

Research progress of Chinese patent technology of protein polypeptide drug liposome

作　　者：雷耀龙 张珮明 陈矛[1] LEI Yaolong;ZHANG Peiming;CHEN Mao(Pharmaceutical and Biological Invention Examination Department,China National Intellectual Property Administration,Beijing 100088)

机构地区：[1]国家知识产权局专利局医药生物发明审查部,北京100088

出　　处：《药物评价研究》2021年第7期1562-1567,共6页Drug Evaluation Research

摘　　要：蛋白多肽类药物脂质体是将蛋白多肽类药物用脂质体包封后形成的载药脂质体,具有靶向、缓释、良好的稳定性等优点。综述了2000年以来中国专利申请中涉及的新型蛋白多肽类药物脂质体,包括凝胶型脂质体、前体脂质体、长循环脂质体、免疫脂质体、柔性脂质体、pH敏感脂质体、配体修饰脂质体、磁性纳米脂质体、多囊脂质体,为继续开发新型的蛋白多肽类药物脂质体提供新的思路。Protein polypeptide drug liposome are drug-loaded liposome formed by encapsulating protein polypeptide drug in liposome,which has the advantages of targeting,sustained release and good stability.The novel protein polypeptide drug liposome involved in Chinese patent applications including gel-type liposome,proliposome,long-circulating liposome,immunoliposome,flexible liposome,pH-sensitive liposome,ligand-modified liposome,magnetic nano-liposome,multivesicular liposome since 2000 were reviewed,in order to provide new ideas for the development of protein polypeptide drug liposome.

关 键 词：蛋白多肽类药物 脂质体 磷脂 中国专利 

分 类 号：R945[医药卫生—微生物与生化药学]